Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022011314 - POLYMORPHS OF A GABAA α5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT

Publication Number WO/2022/011314
Publication Date 13.01.2022
International Application No. PCT/US2021/041179
International Filing Date 09.07.2021
IPC
C07D 487/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
12in which the condensed system contains three hetero rings
14Ortho-condensed systems
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
16Anti-Parkinson drugs
A61P 25/18 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
A61P 25/28 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applicants
  • AGENEBIO, INC. [US]/[US]
Inventors
  • GANDLA, Deepa
  • GREGG, Brian
  • HEGDE, Vishnumrthy
  • PARENT, Stephen, D.
  • HOUSTON, Travis, Lee
Agents
  • HALEY, James, F., Jr.
  • MANGASARIAN, Karen
  • GUMMOW, Brian, M.
Priority Data
63/050,64210.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) POLYMORPHS OF A GABAA α5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT
(FR) POLYMORPHES D'UN AGONISTE GABAA α5 ET MÉTHODES D'UTILISATION DANS LE TRAITEMENT D'UNE DÉFICIENCE COGNITIVE
Abstract
(EN) Crystalline forms of a GABAA α5 agonist, pharmaceutical compositions and combinations comprising those crystalline forms, their use in methods of treating cognitive impairment associated with central nervous system (CNS) disorders, cognitive impairment associated with brain cancer, the brain cancer itself or Parkinson's disease psychosis and methods of producing the crystalline forms.
(FR) L'invention concerne des formes cristallines d'un agoniste GABAA α5, des compositions pharmaceutiques et des combinaisons comprenant ces formes cristallines, leur utilisation dans des procédés de traitement d'une déficience cognitive associée aux troubles du système nerveux central (SNC), d'une déficience cognitive associée au cancer du cerveau, du cancer du cerveau lui-même ou de la psychose de la maladie de Parkinson, ainsi que des procédés de production des formes cristallines.
Latest bibliographic data on file with the International Bureau